Chapter 5. Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models

  1. Dietmar W. Siemann3,4
  1. Mumtaz V. Rojiani1 and
  2. Amyn M. Rojiani2

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch5

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

How to Cite

Rojiani, M. V. and Rojiani, A. M. (2006) Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch5

Editor Information

  1. 3

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 4

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. 1

    Department of Pathology, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA

  2. 2

    Department of Oncology and Pathology, H. Lee Moffit Cancer Center and Research Institute, University of South Florida, 12901 Bruce B. Downs Boulevard, MDC 11, Tampa, FL 33612, USA

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436

SEARCH

Keywords:

  • vascular-disrupting agents in preclinical models;
  • effects of treatment;
  • Vascular disrupting agents (VDA);
  • targeting tumor vasculature;
  • combretastatin and ZD6126;
  • tumor supportive blood vessel attack;
  • intratumoral vascular damage;
  • human Kaposi's sarcoma (KSY-1) and renal cell carcinoma Caki-1 xenograft

Summary

This chapter contains sections titled:

  • Introduction

  • Animal models

  • Morphologic and morphometric analysis

  • Effects of treatment

  • Acknowledgments

  • References